Key statistics
As of last trade Genfit SA (XUP:STU) traded at 5.05, -7.17% below its 52-week high of 5.44, set on May 30, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.84 |
---|---|
High | 5.11 |
Low | 4.84 |
Bid | 4.78 |
Offer | 5.74 |
Previous close | 5.07 |
Average volume | 22.22 |
---|---|
Shares outstanding | 49.94m |
Free float | 43.42m |
P/E (TTM) | 14.98 |
Market cap | 254.69m EUR |
EPS (TTM) | 0.3404 EUR |
Data delayed at least 15 minutes, as of Oct 08 2024.
More ▼
Announcements
- GENFIT : Iqirvo® d’Ipsen (elafibranor) reçoit l’approbation UE en tant que traitement first-in-class de la Cholangite Biliaire Primitive consécutivement à l’approbation accélérée de la FDA américaine
- GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval
- GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate Update
- GENFIT : Résultats financiers du premier semestre 2024 et point sur les activités de la Société
- GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis
- GENFIT : Avis positif du Comité des médicaments à usage humain (CHMP) pour l’Iqirvo® (élafibranor) d’Ipsen dans la Cholangite Biliaire Primitive
- GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
- GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial
- GENFIT : Les nouvelles recommandations de pratique clinique de l'EASL-EASD-EASO pour la MASLD incluent NIS2+® comme outil-clé pour la détection de la MASH à risque
- GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH
More ▼